But what is the real problem? [Two-Stage / GS Designs]

posted by Mikalai  – Belarus, 2018-06-07 17:47 (2929 d 23:13 ago) – Posting: # 18865
Views: 8,612

Good afternoon everyone
I just would like to clarify a bit the situation. We have a drug and do not know it CV. We take an arbitrary sample and then calculate the CV and real GMR in the first stage. In the second stage, we, if I understand correctly, should calculate post-hoc power and recalculate the sample size with the data (GMR and CV) obtained in the first stage, if bioequivalence has not been achieved in the first stage. But what to do, if we have got bad GMR(0,83), whatever CV and low power (around 30) in the first stage. In this case, as I understand, we should recruit much more subjects according to our protocol. The questions, how can we avoid slipping into "forced bioequivalence"? Or should we go straight away and recruit this large number of subjects? What should be put into the protocol?
Best regards,
Mikalai

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,570 registered users;
105 visitors (0 registered, 105 guests [including 14 identified bots]).
Forum time: 17:00 CEST (Europe/Vienna)

The idea is to try and give all the information to help others
to judge the value of your contribution;
not just the information that leads to judgment
in one particular direction or another.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5